Refractory Hypereosinophilic Syndrome With Clonal T-Cell Receptor Rearrangement Treated With JAK Inhibition Following Incomplete Response to IL-5 Blockade. (PubMed, Case Rep Hematol) - Sep 6, 2026 - "Despite prior hydroxyurea therapy, prolonged treatment with mepolizumab, and repeated corticosteroid courses, the patient developed recurrent disease with an absolute eosinophil count of 2760/μL. Ruxolitinib was initiated while IL-5 inhibition was continued...This case highlights the potential role of JAK inhibition as adjunctive therapy in refractory HES with clonal T-cell receptor rearrangement. Further studies are needed to define the safety, durability, and optimal integration of JAK inhibition in patients with refractory eosinophilic disorders."
Journal • Eosinophilia • Hematological Disorders • Hematological Malignancies • Hypereosinophilic Syndrome • Immunology • Oncology • IL5
|
|
Gregory Bongers; Kevin Wayne McKaughan; Phu V Truong
|